Screener
Revolution Medicines, Inc. RVMD Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Revolution Medicines, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-208969
FAQ
- What is Revolution Medicines, Inc.'s debt-to-equity?
- Revolution Medicines, Inc. (RVMD) reported debt-to-equity of 0.1× in Q1 2026.
- How has Revolution Medicines, Inc.'s debt-to-equity changed year-over-year?
- Revolution Medicines, Inc.'s debt-to-equity increased by 61.6% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Revolution Medicines, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Revolution Medicines, Inc.'s debt-to-equity has grown at a 7.1% compound annual growth rate (CAGR), from 0.1× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Revolution Medicines, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude